Biogen and Eisai Terminate P-III ENGAGE and EMERGE Study for Alzheimer's Disease
Shots:
- The termination is based on P-III EMERGE and ENGAGE study results assessing Aducanumab vs PBO in ~ 3-200 patients with mild cognitive impairment due to Alzheimer’s disease and dementia across the world
- The termination is due to its inability to meet 1EPs resulted in the loss of ~$18B to Biogen. Biogen also terminates P-II EVOLVE study of Aducanumab and the long-term extension of PRIME leads to falling in Biogen’s stock price up to 28%
- Aducanumab (BIIB037) is a mAb evaluated for the treatment of Alzheimer’s disease. On Oct-2017 Biogen & Eisai collaborated for the development & commercialization of aducanumab globally
Click here to read full press release/ article
| Ref: Biogen | Image: Biogen
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com